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ABSTRACT
Introduction: Cutaneous tuberculosis (TBC) is
a chronic disease caused by Mycobacterium
tuberculosis, and is present in less than 1–2% of
all TBC cases. The current problem with
diagnosis is the demonstration of bacillus in
the skin, especially paucibacillar forms, where
sources like polymerase chain reaction (PCR)
have improved diagnostic capacity.
Case Presentation: Two cases of cutaneous TBC
are reported. The first patient was 52-year-old
woman with facial erythematous papulo-nodular
lesions which had been developing for 4 months,
and had previously been treated as acne rosacea,
with partial response. Histopathological studies
showed chronic granulomatous inflammation.
TBC was suspected, so PCR was performed, which
showed positive for M. tuberculosis. The second
case was a 43-year-old woman with a facial
rosaceiform plaque which began 6 months
previously, and was treated as rosacea without
any change for 5 months. Skin biopsy and PCR
were positive for TBC. Both cases were treated
using primary schedule for TBC, and both
presented a favorable response.
Discussion: A clinical profile called
Lewandowsky’s rosacea-like eruption has been
previously described. The condition has been
questioned for years and was later removed from
the spectrum of tuberculids and cutaneous TBC
for not being able to isolate microorganisms in
skin samples, a situation that might now change.
In paucibacillar forms, when culture and staining
are negative and TBC is still suspected, it is
recommended to use DNA amplification by PCR
for an accurate diagnosis. Both cases bring up the
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concern about once again bringing
Lewandowsky’s rosaceiform eruption into the
spectrum of cutaneous TBC, and the discussion
about the current definition of tuberculid.
Keywords: Lewandowsky; Polymerase chain
reaction; Tuberculid; Tuberculosis
INTRODUCTION
Cutaneous tuberculosis (TBC) is a chronic
disease caused by Mycobacterium tuberculosis
and occurs in less than 2% of all cases of
extrapulmonary TBC, with an incidence of
0.5–0.6%, and an estimated association
between cutaneous and visceral TBC of 28% of
all cases [1]. It can appear as a manifestation of a
systemic infection, although it can also exist as
primary cutaneous TBC [1, 2]. The most
frequent forms are scrofuloderma and lupus
vulgaris [3, 4]. Clinical manifestations of
cutaneous TBC can be classified by their
dissemination in endogenous and exogenous
infections [5], and according to local bacterial
concentrations in multibacillary (high bacillary
concentration) and paucibacillary (low bacillary
concentration) lesions [4], in which extreme
tuberculids are found [6]. Multibacillary
forms can be caused by direct inoculation
(tuberculous chancre), by continuity
(scrofuloderma, periorificial cutaneous
tuberculosis), or by hematogenous spread
(acute miliary tuberculosis and tuberculous
gumma), while the paucibacillary forms of
cutaneous TBC can be produced by direct
inoculation (tuberculosis verrucosa cutis, lupus
vulgaris in some cases, and tuberculids) or by
hematogenous dissemination (lupus vulgaris
and tuberculids) [5]. In the case of
multibacillary forms, cultures and stains like
Ziehl–Neelsen usually show positive results for
M. tuberculosis, confirming diagnosis by this way
[2, 4, 6]. However, in paucibacillary forms, due
to the low bacillar concentration found locally
in lesions, tests for bacillus may be negative.
The actual problem of diagnosis in cutaneous
TBC is therefore the demonstration of bacillus
in skin biopsies, particularly in paucibacillary
forms. This has forced use of new diagnostic
resources, and polymerase chain reaction (PCR)
has improved global diagnostic accuracy [7–9].
In this article, two cases of cutaneous TBC with
histopathology of tuberculid and rosaceiform
lesions are presented; both cases were diagnosed
using PCR. In addition, a brief literature review
will discuss reconsidering Lewandowsky’s
rosaceiform eruption [10, 11] once again into
the spectrum of cutaneous TBC.
CASE PRESENTATION
Case 1
A 52-year-old Chilean woman presented with
facial erythematous papulo-nodular and
pruriginous lesions which first occurred
4 months previously in both glabellar regions.
These legions extended progressively to the rest
of the face, with confluence zones and an
association with scratching (Fig. 1). She had no
relevant medical history or contact with patients
with known TBC, and had been vaccinated with
Bacillus Calmette–Gue´rin (BCG) after birth. She
had been previously treated for 3 months
for acne rosacea using different drug therapies
(oral doxycycline 100 mg every 12 h, followed
by oral isotretinoin 20 mg per day, and topical
treatment with alpha-bisabolol 1% and
metronidazole gel 1%) with partial response.
Laboratory examinations [C-reactive protein,
C3, C4, anti-neutrophil cytoplasmic antibodies
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(ANCA), anti-proteinase 3 (anti-PR3), anti-
myeloperoxidase (anti-MPO), lupus
erythematosus (LE) cells in peripheral blood
sample] were either negative or in the normal
range, but an antinuclear antibody (ANA) test
was positive in 1:640 dilution with NuMA-1
pattern. Lupus erythematosus was suspected, so
skin biopsy and direct immunofluorescence
assay (IFD) were performed. Histopathological
study showed chronic histiocitary and
lymphoplasmocitary inflammatory process,
with numerous granulomas with central
caseificant necrosis and giant multinucleated
Langerhans cells (Fig. 2) (cytology and
histopathology laboratory, Catholic University
Health Network), while IFD was negative for C3,
immunoglobulin A (IgA), IgG, IgM and fibrin.
Because of these findings, cutaneous TBC was
suspected, and so PCR for M. tuberculosis was
requested. PCR technique was done using
amplification in duplicate for sequence IS6110
[specific for Mycobacterium tuberculosis
complex (MTC)] [12]. Evaluation of DNA’s
integrity from the sample was performed by
amplification of human beta-globin gene
(positive internal control) and a water-only
sample (H2O), to discard the possibility of
contamination (negative external control) [13]
(cytology and histopathology laboratory,
Catholic University health network). PCR
result was positive for TBC (Fig. 3). Tuberculin
test with Mantoux technique [purified protein
derivative (PPD)] was requested to determine her
sensitivity to the bacillus (injection of 2
tuberculin units per 0.1 mL volume, using PPD
RT-23) [14], and resulted in positive erythema
and 5 mm of induration 72 h later (assessed at
Medical Specialties Center, Carlos Van Buren
Hospital, Valparaiso). A chest radiograph (X-ray)
and computed tomography (CT) scan of thorax,
abdomen and pelvis, urine exams and serum
chemistry panel were all negative. Treatment
was started with a primary schedule of 6 months
(using isoniazid 300 mg ? rifampicin 600 mg ?
pyrazinamide 1,500 mg ? ethambutol 1,200 mg
daily for the first 2 months; and isoniazid
Fig. 1 Papulo-erythematous lesions, similar to those
presented in acne rosacea
Fig. 2 Cutaneous biopsy, H–E stain, 1009. Necrotizing
granulomatous dermatitis with caseiﬁcation, and Langerhans
cells located in deeper reticular dermis layer
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800 mg ? rifampicin 600 mg for the subsequent
4 months). The patient responded positively to
treatment, evident after 30 days of treatment,
with complete clearance of lesions at the end of
the treatment (Fig. 4).
Case 2
A 43-year-old woman presented with a
rosaceiform plaque, which had been
developing for 6 months, with papules and
telangiectasies, and erythematous base in her
right cheek (Fig. 5). There was no relevant
medical history, or contact with patients with
known TBC, and she had been vaccinated with
BCG after birth. Treatment for Rosacea was
started, with no changes over 5 months.
Because of the persistence of the lesions and
the poor therapeutic response, skin biopsy and
IFD were indicated. Histopathological tests also
showed superficial dermis with marked and
diffuse lymphocitary infiltrate, with
epithelioid histiocytes and formation of
granulomas; results that were compatible with
Fig. 3 Electrophoresis in agarose gel for the products of
double ampliﬁcation of the insertion sequence IS 6110,
speciﬁc for Mycobacterium tuberculosis complex (MTC).
Column 1 DNA extract from cutaneous sample. Column 2
duplicate of line 1. Column 3 evaluation of the sampling
DNA integrity by ampliﬁcation of the human beta-globin
gene (positive internal control), that shows good DNA
preservation. Line 4 water-only sample (H2O) without
ampliﬁcation that discards the possibility of contamination
(negative external control). Column 5 DNA stair of 100
bases pairs, used for measuring the products. Interpretation
of the meaning of positive ampliﬁcation of IS6110, speciﬁc
for MTC, must always be done in the clinical and
histopathological context of the sample sent for analysis
Fig. 4 Medical control at 6 months of treatment using
primary schedule for tuberculosis, with signiﬁcant
improvement and atrophic scars as sequels
Fig. 5 Cheek with a rosaceiform plaque, papules and
telangiectasies
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tuberculids (Fig. 6) (cytology and
histopathology laboratory, Catholic University
Health Network). IFD was negative for C3, C1q,
IgA, IgG, IgM and fibrin. Similarly to Case 1,
presence of M. tuberculosis was suspected as a
diagnostic possibility, and so PCR was
requested. The technique used was carried out
in duplicate, and was consistent in
amplification for the sequences of the heat
shock protein 65 Kd (generic for
Mycobacterium) and IS6110 (specific for MTC)
[12]. At the same time, DNA integrity of the skin
sample was evaluated by amplification of the
human beta-globin gene (positive internal
control) and a water-only sample (H2O) to
discard the possibility of contamination
(negative external control) [13]. Results of the
PCR were positive for M. tuberculosis (cytology
and histopathology laboratory, Catholic
University Health Network). Tests for PPD
showed negative results, without erythema or
induration (Medical Specialties Center, Carlos
Van Buren Hospital, Valparaiso). Treatment
with primary schedule was started (using the
same schedule as Case 1), showing a rapid
response after 15 days of treatment (Fig. 7).
Tests for the primary focus did not show the
presence of TBC.
Informed consent was obtained from all
patients for being included in the study.
DISCUSSION
Prevalence of TBC in Chile has diminished
during the last few decades, reaching a rate of
13.3/100,000 in 2006 [15]. However, with the
recent outbreak of human immunodeficiency
virus (HIV), the use of novel
immunosuppressive drug therapies, the
emergence of multidrug-resistant TBC strains,
and migrations of population, the current
context may change [5, 16]. This situation is
particularly reflected in HIV and acquired
immune deficiency syndrome (AIDS) patients,
in whom prevalence of TBC is significantly
higher than in the general population [17].
Cases of extrapulmonary TBC are usually more
difficult to diagnose [18]. This is particularly
relevant in paucibacillary forms of cutaneous
TBC, where tests for bacillus may be negative. At
Fig. 6 Cutaneous biopsy, H–E stain, 2009. Caseiﬁcant
granuloma with cells arranged in a palisade
Fig. 7 Results at 15 days of treatment using primary
schedule for tuberculosis
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the extreme of the spectrum are located the
tuberculids (papulonecrotic tuberculid, Bazin’s
erythema induratum, and lichen
scrofulosorum), considered to be cutaneous
hypersensitivity eruptions to M. tuberculosis
that occur in patients previously exposed with
moderate or high levels of immunity against the
microorganism. Tuberculids must comply with
the following conditions: (1) there must be
histopathologic evidence for the presence of
granulomatous inflammation in skin lesions;
(2) there must be a failure to detect M.
tuberculosis in Gram stain and cultures of
affected tissue; (3) there must be cutaneous
lesions that heal with anti-TBC treatment; and
(4) there must be a presence of detectable extra-
cutaneous M. tuberculosis infection (active or
latent), a strongly positive tuberculin skin test,
or a positive interferon-gamma release assay [6,
19].
The clinical features of cutaneous TBC are
diverse and vary from asymptomatic to painful
and pruritic lesions as result of exogenous and
endogenous spread of M. tuberculosis and from
immune-mediated mechanisms [20]. More
often, cutaneous symptoms have appeared
during treatment of pulmonary TBC as
tuberculosis-associated adverse drug reactions
[21]. In our report, the first patient presented
pruriginous lesions. Although rare, pruritus has
been described in cases of tuberculids, especially
in papulonecrotic tuberculids [22–25]. Immune
mechanisms are yet to be understood, but
several authors have proposed that tuberculids
(erythema induratum of Bazin, papulonecrotic
tuberculid) represent delayed-type IV
hypersensitivity reactions mediated by
antigen-specific effector T cells [26–28]. In this
immune reaction, symptoms such as itching are
associated with increased production and
release of cytokines, neurotrophins and
neuropeptides, and are regulated by
infiltrating tissue resident cells [29]. Cytokines
and chemokines are inflammatory mediators
and important activators of sensory nerves,
thereby contributing to neurogenic
inflammation, pain and pruritus [30]. Recent
findings have identified potential classes of
endogenous ‘‘itch mediators’’ and established a
modern concept for the pathophysiology of
pruritus [29, 31].
Due to its low bacillary concentration, it has
been discussed whether to define tuberculids as
produced by the presence of the bacillus in the
skin, or if it is produced by hypersensitivity
reactions [11]. Lewandowsky described in 1917
a clinical form that he called Lewandowsky’s
rosaceiform tuberculid [10], considered initially
inside the spectrum of tuberculids [32–35];
however, this was later criticized by authors
like Snapp et al. [11], because of the
impossibility to isolate microorganisms in skin
samples, and also for failing to show
hypersensitivity to tuberculin. These same
authors suggested in those years that it might
be a new clinical entity by itself, or a variation
of papular rosacea with tuberculoid
histopathology, rather than a clinical
manifestation of TBC. Because of this, it
stopped being considered as part of tuberculids
and cutaneous TBC, and was later renamed as
Lewandowsky’s rosaceiform eruption, also
called lupus miliaris disseminatus faciei
(LMDF), acne agminata, and acnitis [36–39].
Through the years, in many reports lupus
miliaris disseminatus faciei/Lewandowsky
eruption has been related to TBC, sarcoidosis
and rosacea [38–41], with four different
histopathological forms previously defined (for
LMDF) [41]. It is important to outline that
studies that dismissed Lewandowsky’s eruption
as a form of TBC did not use the same
technology that is now used for diagnostic
purposes. This scenario might actually change
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thanks to the new diagnostic techniques
available, such as amplification of DNA from
M. tuberculosis with PCR. In a number of studies
[7–9], PCR has been shown to be the best
diagnostic alternative when laboratory tests
(e.g., immunohistopathology, Ziehl–Neelsen
stains, Kinyoun, fluorochromic techniques
using Auramine-Rhodamine for acid–alcohol-
resistant bacillus, cultures, and detection of INF-
gamma with QuantiFERON, and ELISpot with
ELISA) are not suitable for diagnosis. PCR has
been reported to have a global sensitivity up to
88% and specificity of 83% for the diagnosis of
cutaneous TBC [7], but the accuracy of PCR
varies depending on a number of factors such as
geographic region, local bacterial
concentrations and the DNA amplification
technique used for PCR [6, 19, 42]. Some
investigations have reported false negative
results that might be explained by variations
in the insertion sequence 6110 (IS6110) in
strains of MTC, and because of a low copy
number of IS6110 in M. tuberculosis strains
described in some regions of the world [43].
PCR with hybridization for DNA amplification
seems to be a good option because of the
advantage that it offers in the reduction of
false negatives [44]. Regarding false positive
results, studies have suggested that instead of
considering carryover contamination of M.
tuberculosis DNA, the possibility of the
presence of DNA sequences homologous to
IS6110 in other microorganisms should be
considered, such as in Shigella sonnei,
Escherichia coli, and other Mycobacteria sp.
[43]. For diagnostic PCRs, multiplexing by
targeting two regions like IS6110 and hsp65
could be a good strategy for reducing false
positives [43, 45], as demonstrated in Case 2.
Even though these results must be taken into
account, conclusions about diagnostic tools
must be made based on systematic reviews of
diagnostic test accuracy before applying it into
clinical decisions. In this context, although PCR
has shown to have high sensitivity and
specificity, with good positive and negative
predictive values, it is preferable to use it as a
confirmatory test in patients with a high pre-
test probability [6]. Both cases reported in this
study bring about concern for reconsidering
Lewandowsky’s rosaceiform eruption as part of
the spectrum of cutaneous TBC, as the presence
of bacillus has been shown in skin samples and
both patients responded positively to anti-TBC
treatment. Due to the fact that these cases
involve extrapulmonary TBC, and according to
what is considered by authors such as Concha
et al. [5], treatment should follow national
schemes for these cases; this is based around a
daily dose of isoniazid, rifampicin, and
pyrazinamide for 2 months, and twice-a-week
dose with isoniazid and rifampicin for 4 more
months [5]. Also, second-line drugs in cases of
resistance, such as quinolones, kanamycin,
amikacin, capreomycin, ethionamide and
cycloserine, must be taken into account;
however, this was not necessary for the cases
presented in this report. Clinical response in
both cases was satisfactory, with complete
resolution of cutaneous lesions at the end of
treatment.
CONCLUSION
Although results of tuberculin tests in both
cases do not suggest hypersensitivity for TBC
bacillus, it seems to be reasonable to revise the
current diagnostic criteria of tuberculids as
being cases with localized eruptions that are
histopathologically compatible with tuberculid.
It is possible that PPD skin tests of the second
patient could be false negative (e.g., because of
anergy status, drug use not properly informed,
bad inoculation technique, etc.), which
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complicates the interpretation of its result. It
will be also interesting to once again discuss
reconsidering Lewandowsky’s rosaceiform
eruption as a form of cutaneous TBC, and to
carry out future analytic studies with sufficient
sample sizes to determine the global diagnostic
capacity of PCR in cutaneous TBC, especially in
paucibacillary forms, and to compare the results
of PCR from clinical, histopathological and
analytic characteristics for the different
presentations of cutaneous TBC.
ACKNOWLEDGMENTS
All authors had full access to all of the data in
this study and take complete responsibility for
the integrity of the data and accuracy of the
data analysis. No funding or sponsorship was
received for this study or publication of this
article. All named authors meet the ICMJE
criteria for authorship for this manuscript,
take responsibility for the integrity of the work
as a whole, and have given final approval for the
version to be published.
Conflict of interest. R. Conlledo, A.
Guglielmetti, M. Sobarzo, F. Woolvett, F.
Bravo, S. Gonza´lez, F. Fich and V. Vial declare
no conflict of interest.
Compliance with ethics
guidelines. Informed consent was obtained
from all patients for being included in the
study.
Special thanks to the Department of Anatomic
Pathology and the Department of Dermatology,
Pontifical Catholic University of Chile, for all
their help and effort regarding diagnosis.
Open Access. This article is distributed
under the terms of the Creative Commons
Attribution Noncommercial License which
permits any noncommercial use, distribution,
and reproduction in any medium, provided the
original author(s) and the source are credited.
REFERENCES
1. Pe´rez B, Pifarre R, de Vera CV, et al. Cutaneous
tuberculosis caused by Mycobacterium tuberculosis,
an uncommon pathology. An Med Interna.
2006;23(11):560–1.
2. Handog EB, Gabriel TG, Pineda RT. Management of
cutaneous tuberculosis. Dermatol Ther.
2008;21(3):154–61.
3. Saritha M, Parveen BA, Anandan V, Priyavathani
MR, Tharini KG. Atypical forms of lupus vulgaris—a
case series. Int J Dermatol. 2009;48(2):150–3.
4. Bravo F, Gotuzzo E. Cutaneous tuberculosis. Clin
Dermatol. 2007;25(2):173–80.
5. Concha MR, Fich FS, Rabagliati RB, Pinto CS, Rubio
RL, Navea OD, Gonza´lez SB. Tuberculosis cuta´nea:
reporte de dos casos y revisio´n de la literatura. Rev
Chil Infect. 2011;28(3):262–8.
6. Frankel A, Penrose C, Emer J. Cutaneous
tuberculosis: a practical case report and review of
the dermatologist. J Clin Aesthet Dermatol.
2009;2(10):19–27.
7. Abdalla CM, de Oliveira ZN, Sotto MN, Leite KR,
Canavez FC, de Carvalho CM. Polymerase chain
reaction compared to other laboratory findings and
to clinical evaluation in the diagnosis of cutaneous
tuberculosis and atypical mycobacteria skin
infection. Int J Dermatol. 2009;48(1):27–35.
8. Padmavathy L, Rao L, Veliath A. Utility of
polymerase chain reaction as a diagnostic tool in
cutaneous tuberculosis. Indian J Dermatol Venereol
Leprol. 2003;69(3):214–6.
9. Almaguer-Cha´vez J, Ocampo-Candiani J, Rendo´n A.
Current panorama in the diagnosis of cutaneous
tuberculosis. Actas Dermosifiliogr.
2009;100(7):562–70.
10. Lewandowsky F. Ueber Rosacea-ahnliche
tuberkulide des gesichts. Cor -Bl F schweiz Aerzte.
1917;47:1280.
11. Snapp RH. Lewandowsky’s rosacea-like eruption: a
clinical study. J Invest Derm. 1949;13(4):175–90.
74 Dermatol Ther (Heidelb) (2015) 5:67–76
12. Fletcher HA. Molecular epidemiology of tuberculosis:
recent developments and applications. Curr Opin
Pulm Med. 2001;7(3):154–9.
13. Saiki RK, Chang CA, Levenson CH, et al. Diagnosis
of sickle cell anemia and beta-thalassemia with
enzymatically amplified DNA and nonradioactive
allele-specific oligonucleotide probes. N Engl J Med.
1988;319(9):537–41.
14. Magnusson M, Bentzon MW. Preparation of
purified tuberculin RT 23. Bull World Health
Organ. 1958;19(5):829–43.
15. Zun˜iga MMP, Riquelme C. Reflections about
tuberculosis in Chile. Rev Chil Enf Respir.
2007;23:59–66.
16. Barbagallo J, Tager P, Ingleton R, Hirsch RJ,
Weinberg JM. Cutaneous tuberculosis: diagnosis
and treatment. Am J Clin Dermatol.
2002;3(5):319–28.
17. Villarroel L, Rabagliati R, Balcells ME, Karzulovic L,
Pe´rez C. Prevalence of tuberculosis and its impact
on mortality among HIV infected patients in Chile.
Rev Med Chil. 2008;136(5):578–86.
18. Varas MC, Nieme SC, Barrı´a MC. Cutaneous
tuberculosis. Report of one case. Rev Med Chil.
2012;140(4):493–8.
19. Handog EB, Macarayo MJ. Cutaneous
manifestations of tuberculosis. UpToDate:
Waltham; 2014. http://www.uptodate.com/
contents/cutaneous-manifestations-of-tuberculosis.
Accessed Dec 2, 2014.
20. Lai-Cheong JE, Perez A, Tang V, Martinez A, Hill V,
Menage´ Hdu P. Cutaneous manifestations of
tuberculosis. Clin Exp Dermatol. 2007;32(4):461–6.
21. Kansal HM, Goel S. Cutaneous manifestations in
cases of pulmonary tuberculosis: a clinical profile.
J Indian Acad Clin Med. 2013;14(3–4):284–6.
22. Oh ST, Lee HJ, Youn DH, Kim JW. A case of
papulonecrotic tuberculid combined with
erythema induratum. Korean J Dermatol.
1999;37(11):1703–5.
23. Williams JT, Pulitzer DR, DeVillez RL.
Papulonecrotic tuberculid secondary to
disseminated Mycobacterium avium complex. Int
J Dermatol. 1994;33(2):109–12.
24. Iden DL, Rogers RS 3rd, Schroeter AL.
Papulonecrotic tuberculid secondary to
Mycobacterium bovis. Arch Dermatol.
1978;114(4):564–6.
25. Saporito L, Florena AM, Colomba C, Pampinella D,
Di Carlo P. Prurigo nodularis due to Mycobacterium
tuberculosis. J Med Microbiol. 2009;58(Pt
12):1649–51.
26. Kuramoto Y, Aiba S, Tagami H. Erythema
induratum of Bazin as a type of tuberculid. J Am
Acad Dermatol. 1990;22(4):612–6.
27. Jordaan HF, Schneider JW, Schaaf HS, et al.
Papulonecrotic tuberculid in children. A report of
eight patients. Am J Dermatopathol.
1996;18(2):172–85.
28. Janeway CA Jr, Travers P, Walport M, et al.
Immunobiology: the immune system in health
and disease. 5th ed. New York: Garland Science;
2001. http://www.ncbi.nlm.nih.gov/books/
NBK27136/. Accessed Dec 2, 2014.
29. Raap U, Sta¨nder S, Metz M. Pathophysiology of itch
and new treatments. Curr Opin Allergy Clin
Immunol. 2011;11(5):420–7.
30. Cevikbas F, Steinhoff A, Homey B, Steinhoff M.
Neuroimmune interactions in allergic skin diseases.
Curr Opin Allergy Clin Immunol.
2007;7(5):365–73.
31. Steinhoff M, Bienenstock J, Schmelz M, Maurer M,
Wei E, Bı´ro´ T. Neurophysiological,
neuroimmunological, and neuroendocrine basis of
pruritus. J Invest Dermatol. 2006;126:1705–18.
32. Samtsov AV. Rosacea-like Lewandowski’s
tuberculid. Vestn Dermatol Venerol. 1980;8:49–52.
33. Rothman S, Shapiro A. Rosacealike tuberculid of
Lewandowski. Arch Derm Syphilol. 1946;54:231–3.
34. Aguilera Maruri C, Gay Martinez G. Rosaceiforme
Tubercu´lide Lewandowski. Actas Dermosifiliogr.
1957;48(12):564–73.
35. Rozsı´valova´ V, Kraus Z, Simkova´ M. Rosaceiform
tuberculides (author’s transl. Cesk Dermatol.
1977;52(1):42–5.
36. Bo¨er A, Grover S. A form of rosacea or a distinctive
disease? Dermatopathol Pract Conc. 2008;14(3):8.
37. Ackerman AB, Bo¨er A, Bennin B, Gottlieb GJ.
Histologic diagnosis of inflammatory diseases of
the skin. 3rd ed. New York: Ardor Scribendi Ltd.;
2005.
38. Van de Scheur MR, van der Waal RI, Starink TM.
Lupus miliaris disseminatus faciei: a distinctive
rosacea-like syndrome and not a granulomatous
form of rosacea. Dermatology. 2003;206(2):120–3.
Dermatol Ther (Heidelb) (2015) 5:67–76 75
39. Alonso V, Ramo´n D, Martı´n JM, Monteagudo C,
Molina I, Jorda´ E. Lupus miliaris disseminatus
faciei. Actas Dermosifiliogr. 2005;96(3):182–5.
40. Botella R, Castejo´n P, Sanmartı´n O, Arnedo L,
Guille´n C. Lupus miliaris disseminatus faciei: una
forma infrecuente de rosa´cea. Actas Dermosifiliogr.
1998;89:321–4.
41. Sehgal VN, Srivastava G, Aggarwal AK, Reddy V,
Sharma S. Lupus miliaris disseminatus faciei part II:
an overview. Skinmed. 2005;4(4):234–8.
42. Maurya AK, Kant S, Nag VL, Kushwaha RA, Kumar
M, Dhole TN. Comparative evaluation of IS6110
PCR via conventional methods in rapid diagnosis of
new and previously treated cases of extrapulmonary
tuberculosis. Tuberk Toraks. 2011;59(3):213–20.
43. Sankar S, Kuppanan S, Balakrishnan B, Nandagopal
B. Analysis of sequence diversity among IS6110
sequence of Mycobacterium tuberculosis: possible
implications for PCR based detection.
Bioinformation. 2011;6(7):283–5.
44. dos Santos JB, Figueiredo AR, Ferraz CE, de Oliveira
MH, da Silva PG, de Medeiros VL. Cutaneous
tuberculosis: diagnosis, histopathology and
treatment—part II. An Bras Dermatol.
2014;89(4):545–55.
45. Sankar S, Ramamurthy M, Nandagopal B, Sridharan
G. An appraisal of PCR-based technology in the
detection of Mycobacterium tuberculosis. Mol
Diagn Ther. 2011;15(1):1–11.
76 Dermatol Ther (Heidelb) (2015) 5:67–76
